These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cardiovascular disease and osteoporosis: is there a link between lipids and bone? Burnett JR; Vasikaran SD Ann Clin Biochem; 2002 May; 39(Pt 3):203-10. PubMed ID: 12038594 [TBL] [Abstract][Full Text] [Related]
4. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. Hamerman D QJM; 2005 Jul; 98(7):467-84. PubMed ID: 15955801 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological agents and natural compounds: available treatments for osteoporosis. Martiniakova M; Babikova M; Omelka R J Physiol Pharmacol; 2020 Jun; 71(3):. PubMed ID: 32991310 [TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates: the first 40 years. Russell RG Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003 [TBL] [Abstract][Full Text] [Related]
10. [Recent topics on therapeutics for osteoporosis in patients complicated with vascular diseases]. Shioi A Clin Calcium; 2001 Apr; 11(4):469-73. PubMed ID: 15775544 [TBL] [Abstract][Full Text] [Related]
11. Myeloma bone disease: pathogenesis, current treatments and future targets. Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study. Marocco C; Zimatore G; Mocini E; Fornari R; Iolascon G; Gallotta MC; Bimonte VM; Baldari C; Lenzi A; Migliaccio S Int J Environ Res Public Health; 2021 Feb; 18(4):. PubMed ID: 33579002 [TBL] [Abstract][Full Text] [Related]
13. [OPG/RANKL: role and therapeutic target in osteoporosis]. Marie P; Halbout P Med Sci (Paris); 2008 Jan; 24(1):105-10. PubMed ID: 18198124 [TBL] [Abstract][Full Text] [Related]
14. Effect of Bisphosphonates on the Levels of Rankl and Opg in Gingival Crevicular Fluid of Patients With Periodontal Disease and Post-menopausal Osteoporosis. Verde ME; Bermejo D; Gruppi A; Grenón M Acta Odontol Latinoam; 2015 Dec; 28(3):215-21. PubMed ID: 27095621 [TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates: from the laboratory to the clinic and back again. Russell RG; Rogers MJ Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031 [TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of anti-RANKL antibody in depression-like phenotype, inflammatory bone markers, and bone mineral density in male susceptible mice after chronic social defeat stress. Zhang J; Fujita Y; Chang L; Pu Y; Qu Y; Wang S; Hashimoto K Behav Brain Res; 2020 Feb; 379():112397. PubMed ID: 31790783 [TBL] [Abstract][Full Text] [Related]
18. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches. Langdahl B Bone; 2020 Oct; 139():115516. PubMed ID: 32622871 [TBL] [Abstract][Full Text] [Related]
19. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Dempster DW; Lambing CL; Kostenuik PJ; Grauer A Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513 [TBL] [Abstract][Full Text] [Related]